JNJ
Johnson & Johnson
Price History
Why Is JNJ ▼ Down Today?
-0.27%
Full AI analysis generates after market close. Showing live price data.
Financial Highlights
Income Statement
Balance Sheet
Cash Flow
Highly Regarded Analysis
Executive Summary
Johnson & Johnson (JNJ) is a diversified healthcare giant, operating in innovative medicine and MedTech divisions after divesting its consumer health business, Kenvue, in 2023. The company has a strong focus on oncology, immunology, and neurology, backed by a robust R&D pipeline. JNJ recently reached an all-time high price of $281.07 on September 1, 2026, and has shown a 51.74% increase over the last year. Analysts generally have a 'Buy' or 'Moderate Buy' rating for the stock, with a median 12-month price target of approximately $281. Despite facing legal challenges and patent expirations, JNJ is known for its stable performance, consistent dividend growth, and strong financial health.
Bull Case
The bull case for JNJ is driven by its strong pipeline in innovative medicine, particularly in oncology, where management aims to triple sales to over $50 billion by 2030. Recent FDA approvals such as IMAAVY (nipocalimab) for warm autoimmune hemolytic anemia and the Ottava robotic surgery platform are expected to fuel growth. The depth of its pipeline, including new therapies for rare diseases and a potential 'pipeline-in-a-product' like nipocalimab, signals significant future revenue streams. Increased adoption of newly launched products in MedTech is also anticipated to contribute to better growth in 2026. Furthermore, JNJ's fortress balance sheet and consistent dividend growth make it an attractive defensive compounder.
Bear Case
The bear case for JNJ centers on significant legal and regulatory challenges, including ongoing talc litigation and patent expirations, particularly the 'Stelara cliff' which could create a substantial revenue gap. The company faces intense competition and potential biosimilar erosion for key pharmaceutical products. Some valuation models suggest JNJ may be trading above its fair value, implying a potential downside. Insider selling near all-time highs and safety alerts related to products like Abiomed heart pump controllers also present concerns. Global economic and political uncertainties, as well as evolving ESG expectations, could further impact operations and financial performance.
Technical Outlook
JNJ's stock has seen significant upside over the past year, with a 51.74% increase, and reached an all-time high of $281.07 on September 1, 2026. While the stock experienced a -2.22% decrease in the past 24 hours to $269.12, it has shown a 5.17% rise over the last month. The stock's low beta (around 0.23 to -0.53) suggests relatively low volatility compared to the broader market. The current price is near the consensus analyst target, indicating it may be fairly valued in the short term, with potential for further upside if key catalysts materialize.
Fundamental Health
Johnson & Johnson exhibits robust fundamental health with a diverse revenue base from its innovative medicine and MedTech segments. The company reported Q2 2026 earnings per share (EPS) of $2.90, exceeding analyst estimates of $2.85. Quarterly revenue for Q2 2026 was $25.31 billion, surpassing the estimated $25.06 billion and representing a 6.6% year-over-year increase. For the full year 2025, revenue was $94.19 billion, a 6.05% increase from the previous year, with earnings of $26.80 billion, a 90.56% increase. JNJ is a dividend aristocrat, having increased its dividend for 56 consecutive years, with a dividend yield of approximately 1.92% to 1.99%. The company maintains a strong balance sheet and generates exceptional cash flow.
Key Catalysts
- Next earnings report on October 13, 2026
- Successful commercialization and market penetration of the Ottava robotic surgery platform
- Further approvals and expanded indications for key pipeline drugs like IMAAVY (nipocalimab) and ICOTYDE (icotrokinra)
- Continued growth in the oncology franchise, including DARZALEX, CARVYKTI, and TECVAYLI
- Resolution of major litigation, particularly concerning talc-related claims, reducing financial uncertainty
Sources
This analysis was conducted by Highly Regarded's proprietary market analysis engine. It is not financial advice. Always do your own research and consult a financial advisor before making investment decisions.
Go Deeper on JNJ
Key Stats
Next Earnings
JNJ News
No recent news for JNJ.
